WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

A Review on – Pancreatic Cancer

Azra Qureshi[1], Sakshi Kakde[2], Akansha P. S. Vishvakarma[3], Dr. Javed Khan[4]

[1]Scholar of index institute of pharmacy Malwanchal University Indore (M.P.)
[2]Scholar of index institute of pharmacy, Malwanchal University, Indore, (M.P.)
[3]Associate professor of index institute of pharmacy, Malwanchal University, Indore (M.P.)
[4]Principal of index institute of pharmacy, Malwanchal University, Indore (M.P.)

ABSTRACT:

Pancreatic cancer remains one of the most lethal malignancies, characterized by late-stage diagnosis, aggressive progression, and limited therapeutic options. This review aims to synthesize current knowledge on the epidemiology, pathophysiology, diagnostic challenges, and treatment modalities of pancreatic cancer. Despite advances in medical imaging and molecular biology, early detection remains elusive, contributing to poor prognostic outcomes. The review explores the genetic and environmental risk factors associated with pancreatic cancer, including smoking, chronic pancreatitis, diabetes mellitus, and familial genetic syndromes. It also highlights recent advancements in understanding the molecular pathways involved in pancreatic tumorigenesis, including mutations in KRAS, p53, SMAD4, and BRCA2. Current treatment strategies, such as surgical resection, chemotherapy, radiation therapy, and targeted therapies, are evaluated, with a focus on their efficacy and limitations. Emerging approaches, including immunotherapy and personalized medicine, offer hope for improved outcomes. However, significant challenges remain, necessitating continued research and innovative clinical trials. This review underscores the urgent need for novel biomarkers for early detection and more effective therapeutic strategies to improve the prognosis of pancreatic cancer patients.

Keywords: Pancreatic cancer, Epidemiology, Pathophysiology, Diagnostic challenges, Treatment modalities, Early detection, Genetic risk factors, KRAS mutations, p53, SMAD4, BRCA2

1. INTRODUCTION:

Pancreatic cancer stands as one of the most formidable and fatal cancers, with a dismal five-year survival rate of under 10%. Globally, it is the seventh leading cause of cancer deaths, with its incidence on the rise. The insidious nature of the disease means it often progresses without noticeable symptoms, resulting in diagnoses at advanced stages and limited treatment options.

The pancreas, an organ crucial for both digestion and glucose regulation, consists of endocrine and exocrine components. The majority of pancreatic cancers, specifically over 90%, are pancreatic ductal adenocarcinomas (PDAC) originating from the exocrine pancreas. PDAC is particularly aggressive and notoriously resistant to standard treatments, contributing significantly to its high mortality rate.

A deeper understanding of the intricate biology and molecular mechanisms of pancreatic cancer is essential for the development of effective diagnostic and treatment strategies. Mutations in key genes such as KRAS, p53, SMAD4, and BRCA2 play pivotal roles in the development of pancreatic cancer. Additionally, various environmental and lifestyle factors, including smoking, chronic pancreatitis, obesity, and diabetes, have been associated with an increased risk of the disease.

Despite advancements in imaging technology, molecular biology, and therapeutic interventions, early detection of pancreatic cancer remains a formidable challenge. Most cases are diagnosed at an advanced stage, making curative surgery impossible for many patients. This underscores the urgent need for new biomarkers and innovative treatment strategies to improve patient outcomes.

This review seeks to consolidate current knowledge on pancreatic cancer, covering its epidemiology, pathophysiology, risk factors, diagnostic hurdles, and treatment options. It will also discuss recent research advancements and emerging therapies that offer hope for more effective management and better prognoses for those afflicted by this devastating disease.

Types of Pancreatic Cancer

Exocrine Tumors

- Pancreatic Ductal Adenocarcinoma (PDAC)
- Acinar Cell Carcinoma

- Adenosquamous Carcinoma
- Colloid Carcinoma
- Signet Ring Cell Carcinoma

Endocrine Tumors (PNETs)

- Insulinomas
- Gastrinomas
- Glucagonomas
- VIPomas
- Somatostatinomas
- Non-Functional PNETs

2. PROBLEM STATEMENT

Pancreatic cancer remains one of the most lethal malignancies, characterized by late-stage diagnosis, rapid disease progression, and limited effective treatment options. Despite advancements in medical technology and molecular biology, the overall survival rate for pancreatic cancer patients has not significantly improved over the past few decades. The primary challenges contributing to the high mortality rate include:

1. **Late Diagnosis**: Pancreatic cancer often presents with nonspecific symptoms, leading to diagnosis at advanced stages when curative treatments are no longer viable.
2. **Aggressive Nature**: The disease is highly aggressive, with a propensity for early metastasis and resistance to conventional therapies.
3. **Limited Treatment Options**: Current treatment modalities, including surgery, chemotherapy, and radiation therapy, offer limited efficacy, particularly in advanced stages of the disease.
4. **Lack of Early Detection Biomarkers**: There is a critical need for reliable biomarkers to enable early detection and improve the chances of successful treatment.
5. **Genetic and Environmental Risk Factors**: Understanding the complex interplay of genetic mutations (e.g., KRAS, p53, SMAD4, BRCA2) and environmental/lifestyle factors (e.g., smoking, chronic pancreatitis, obesity, diabetes) is essential for developing targeted prevention and treatment strategies.
6. **Resistance to Treatment**: Pancreatic tumors often develop resistance to conventional therapies, necessitating the development of novel therapeutic approaches.

3. EPIDEMIOLOGY AND RISK FACTORS

Epidemiology

Pancreatic cancer is a significant global health burden, ranking as the seventh leading cause of cancer-related deaths worldwide. The incidence and mortality rates have been rising, with an estimated 495,000 new cases and 466,000 deaths annually. The disease predominantly affects older adults, with the majority of cases diagnosed in individuals over the age of 65. There is a slight male predominance, and racial disparities exist, with African Americans experiencing higher incidence and mortality rates compared to other racial groups.

Risk Factors

Genetic Factors

- **Inherited Genetic Syndromes**: Certain hereditary conditions significantly increase the risk of pancreatic cancer. These include familial atypical multiple mole melanoma (FAMMM) syndrome, hereditary breast and ovarian cancer (HBOC) syndrome (linked to BRCA1 and BRCA2 mutations), Lynch syndrome, and Peutz-Jeghers syndrome.
- **Family History**: Individuals with a first-degree relative diagnosed with pancreatic cancer have an increased risk, suggesting a genetic predisposition.

Lifestyle and Environmental Factors

- **Smoking**: Tobacco use is a well-established risk factor, with smokers having approximately double the risk of developing pancreatic cancer compared to non-smokers. The risk increases with the duration and intensity of smoking.

- **Obesity**: Higher body mass index (BMI) is associated with an increased risk of pancreatic cancer. Obesity-related metabolic changes, such as insulin resistance, may contribute to this elevated risk.
- **Diet**: Diets high in red and processed meats and low in fruits and vegetables may increase the risk. Conversely, diets rich in fruits, vegetables, and whole grains may have a protective effect.

Medical Conditions

- **Diabetes Mellitus**: Long-standing diabetes is associated with an increased risk of pancreatic cancer. Conversely, new-onset diabetes in older adults may be an early symptom of the disease.
- **Chronic Pancreatitis**: Chronic inflammation of the pancreas, often due to long-term alcohol use or hereditary pancreatitis, significantly increases the risk of pancreatic cancer.
- **Infections**: Chronic infections, such as Helicobacter pylori and hepatitis B, have been linked to an increased risk, though the evidence is not as strong as for other factors.

Occupational Exposures

- **Chemical Exposure**: Occupational exposure to certain chemicals, such as pesticides, dyes, and petrochemicals, may increase the risk of pancreatic cancer.

Other Factors

- **Age**: The risk of pancreatic cancer increases with age, with most cases occurring in individuals over 65.
- **Gender**: Males have a slightly higher risk of developing pancreatic cancer compared to females.
- **Race**: African Americans have a higher incidence and mortality rate from pancreatic cancer compared to other racial groups, which may be due to a combination of genetic, environmental, and socioeconomic factors.

4. TREATMENT OPTIONS FOR PANCREATIC CANCER

The treatment of pancreatic cancer involves a multimodal approach that depends on the stage of the disease, the patient's overall health, and the specific characteristics of the tumor. The main treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and emerging treatments such as immunotherapy.

I. Surgery

Curative Surgery

- **Whipple Procedure (Pancreaticoduodenectomy)**: This is the most common surgical procedure for tumors located in the head of the pancreas. It involves the removal of the head of the pancreas, part of the small intestine, the gallbladder, and part of the bile duct.
- **Distal Pancreatectomy**: This surgery is performed for tumors located in the body and tail of the pancreas. It involves the removal of the tail and sometimes part of the body of the pancreas, often along with the spleen.
- **Total Pancreatectomy**: Involves removing the entire pancreas, part of the small intestine, part of the stomach, the common bile duct, the gallbladder, the spleen, and nearby lymph nodes.

Palliative Surgery

- **Biliary Bypass**: If the tumor is blocking the bile duct, a biliary bypass can be performed to relieve jaundice and other symptoms.
- **Gastric Bypass**: For tumors obstructing the stomach, a gastric bypass can be done to allow food to pass from the stomach to the small intestine.

II. Chemotherapy

Adjuvant Chemotherapy

- Used after surgery to eliminate any remaining cancer cells and reduce the risk of recurrence.
- Common drugs include gemcitabine and fluorouracil (5-FU).

Neoadjuvant Chemotherapy

- Given before surgery to shrink the tumor and make it more resectable.

- Common regimens include FOLFIRINOX (a combination of leucovorin, fluorouracil, irinotecan, and oxaliplatin) or gemcitabine plus nab-paclitaxel.

Palliative Chemotherapy

- Used in advanced stages to relieve symptoms and prolong survival.
- Commonly used drugs include gemcitabine and nab-paclitaxel.

III. Radiation Therapy

External Beam Radiation Therapy (EBRT)

- Uses high-energy beams to target and destroy cancer cells.
- Often used in combination with chemotherapy (chemoradiation) for locally advanced tumors.

Stereotactic Body Radiation Therapy (SBRT)

- A more precise form of radiation that delivers high doses over fewer sessions.
- Can be used for patients who cannot undergo surgery.

IV. Targeted Therapy

Erlotinib

- A targeted therapy drug that inhibits the epidermal growth factor receptor (EGFR) and is sometimes used in combination with gemcitabine for advanced pancreatic cancer.

Olaparib

- A PARP inhibitor used for patients with BRCA1 or BRCA2 mutations, following platinum-based chemotherapy.

V. Immunotherapy

Checkpoint Inhibitors

- Drugs like pembrolizumab, which target PD-1/PD-L1 pathways, are being explored in clinical trials for pancreatic cancer with specific genetic markers.

Cancer Vaccines

- Experimental vaccines that aim to stimulate the immune system to attack pancreatic cancer cells.

Adoptive Cell Transfer

- A personalized immunotherapy approach where a patient's own immune cells are modified and reintroduced to target cancer cells.

VI. Emerging Therapies and Clinical Trials

Personalized Medicine

- Using genetic profiling of tumors to tailor treatments based on individual mutations and molecular characteristics.

Combination Therapies

- Combining different modalities such as chemotherapy, radiation, and targeted therapy to enhance treatment efficacy.

Novel Agents

- Investigational drugs and treatments being tested in clinical trials, offering hope for new and more effective options.

The treatment of pancreatic cancer requires a personalized and multidisciplinary approach. Surgery remains the cornerstone for potentially curative treatment, but it is only applicable to a minority of patients due to late-stage diagnosis. Chemotherapy, radiation therapy, and targeted therapies play crucial roles in managing the disease, particularly in advanced stages. Emerging treatments, including immunotherapy and personalized medicine, hold promise for improving outcomes. Ongoing research and clinical trials are vital to advancing the understanding and treatment of this challenging disease.

5. RECENT ADVANCEMENTS IN PANCREATIC CANCER TREATMENT

I. Enhanced Diagnostics

- **Liquid Biopsies**: Non-invasive blood tests for detecting genetic mutations and monitoring treatment.
- **Advanced Imaging**: Improved MRI and PET/CT for better tumor visualization and staging.

II. Genetic and Molecular Profiling

- **Comprehensive Genomic Profiling**: Advanced sequencing to identify actionable mutations for personalized treatment.
- **Biomarker Identification**: New biomarkers for early detection and treatment prediction.

III. Targeted Therapies

- **PARP Inhibitors**: Drugs like olaparib for patients with BRCA mutations.
- **KRAS Inhibitors**: New treatments targeting KRAS mutations.

IV. Immunotherapy

- **Checkpoint Inhibitors**: Drugs like pembrolizumab targeting PD-1/PD-L1 pathways.
- **Cancer Vaccines**: Experimental vaccines stimulating immune response against tumors.
- **Adoptive Cell Transfer**: CAR T-cell therapy showing promise in trials.

V. Combination Therapies

- **Chemotherapy and Immunotherapy**: Combined approaches to enhance efficacy.
- **Radiation and Immune Modulation**: Using SBRT with immune modulators for better outcomes.

VI. Personalized Medicine

- **Tailored Treatment**: Customizing therapies based on tumor genetics.
- **Adaptive Trials**: Flexible trial designs for efficient evaluation of new treatments.

VII. Novel Agents

- **Stromal Targeting**: Agents like PEGPH20 to improve drug delivery.
- **Metabolic Pathway Inhibitors**: Targeting unique cancer cell metabolism for new treatment options.

CONCLUSION

Recent strides in pancreatic cancer treatment have brought notable progress in combating this complex disease. Advances in diagnostic methods, such as liquid biopsies and sophisticated imaging techniques, are enhancing early detection and accurate tumor staging. The application of genetic and molecular profiling is facilitating more personalized treatment plans by pinpointing specific mutations and biomarkers.

Targeted therapies, including those aimed at PARP and KRAS mutations, are showing potential in treating these specific cancer alterations. Additionally, immunotherapy approaches, such as checkpoint inhibitors and cancer vaccines, are beginning to offer promising new treatment options. The exploration of combination therapies and novel agents is focused on overcoming resistance and improving therapeutic outcomes.

The shift towards personalized medicine and adaptive clinical trials is making treatment more tailored and effective. While challenges such as early detection and resistance persist, these advancements offer hope for improved management and better patient outcomes. Ongoing research and clinical advancements are essential for translating these innovations into effective treatments and achieving better results for pancreatic cancer patients.

REFERENCES

1. PDQ Adult Treatment Editoria Board Pancreatic Cancer Treatment (Adult) n (PDQ®): Health Professional Version 2002 [PMID: 26389394].
2. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP. Pancreatic cancer. Nat Rev Dis Primers 2016; 2: 16022 [PMID: 27158978 DOI: 10.1038/nrdp.2016.222 .
3. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement JAMA 2019; 322: 438-444 [PMID: 31386141 DOI: 10.1001/jama.2019.10232].

4. Wong MCS, Jiang JY, Liang M, Fang Y, Yeung MS, Sung JJY. Global temporal patterns of pancreatic cancer and association with socioeconomic development. Sci Rep 2017; 7: 3165 [PMID: 28600530 DOI: 10.1038/s41598-017-02997-2].

5. Saad AM, Turk T, Al-Husseini MJ, Abdel-Rahman O. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer 2018; 18: 688 [PMID: 29940910 DOI: 10.1186/ s12885-018-4610-4] .

6. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67: 7-30 [PMID: 28055103 DOI: 10.3322/ caac.21387].

7. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-2921 [PMID: 24840647 DOI: 10.1158/0008-5472.CAN-14-0155].

8. Winter JM, Brody JR, Abrams RA, Lewis NL, Yeo CJ. Chapter 49: Cancer of the Pancreas. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman.

9. Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: A review. Cancer Lett 2016; 381: 269-277 [PMID: 27461582 DOI: 10.1016/j.canlet.2016.07.022].

10. Wood HE, Gupta S, Kang JY, Quinn MJ, Maxwell JD, Mudan S, Majeed A. Pancreatic cancer in England and Wales 1975-2000: patterns and trends in incidence, survival and mortality. Aliment Pharmacol Ther 2006; 23: 1205-1214 [PMID: 16611282 DOI: 10.1111/j.1365-2036.2006.02860.x].